Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19247
Full metadata record
DC FieldValueLanguage
dc.contributor.authorTsimihodimos, V.en
dc.contributor.authorLiberopoulos, E.en
dc.contributor.authorElisaf, M. S.en
dc.date.accessioned2015-11-24T18:58:07Z-
dc.date.available2015-11-24T18:58:07Z-
dc.identifier.issn1873-4286-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19247-
dc.rightsDefault Licence-
dc.subjectAnimalsen
dc.subjectAtherosclerosis/drug therapy/physiopathologyen
dc.subjectDisease Progressionen
dc.subjectFenofibrate/*pharmacologyen
dc.subjectGene Expression Regulation/drug effectsen
dc.subjectHumansen
dc.subjectHypolipidemic Agents/*pharmacologyen
dc.subjectLipoproteins/drug effects/metabolismen
dc.titlePleiotropic effects of fenofibrateen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/19199978-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2009-
heal.abstractFenofibrate represents the most commonly used fibric acid derivative. The drug exerts its metabolic effects by modulating the expression of several genes involved in lipoprotein metabolism. In addition, numerous studies suggest that fenofibrate may also affect the progression of the atherosclerotic process by several lipid-independent mechanisms. This review considers the clinical pharmacology of fenofibrate and the current evidence on the pleiotropic effects of this fibric acid derivative.en
heal.journalNameCurr Pharm Desen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
There are no files associated with this item.


This item is licensed under a Creative Commons License Creative Commons